MedPath

Interpretation Bias Modification for Body Dysmorphic Disorder

Not Applicable
Completed
Conditions
Body Dysmorphic Disorder
Interventions
Behavioral: Interpretation Bias Modification
Behavioral: Progressive Muscle Relaxation
Registration Number
NCT02635152
Lead Sponsor
Florida State University
Brief Summary

The purpose of this study is to determine whether a computerized intervention designed to reduce appearance and evaluation related interpretation biases will reduce symptoms associated with body dysmorphic disorder.

Detailed Description

The present study aims to examine the feasibility of a remote treatment for body dysmorphic disorder delivered via the Internet. To evaluate the efficacy of the IBM protocol we have developed in reducing negative appearance and evaluative related interpretations, we will conduct a two-arm randomized controlled trial over the internet. Individuals with a diagnosis of body dysmorphic disorder (N = 40) will be randomized to one of two conditions: 1) IBM or 2) progressive muscle relaxation. Each condition will consist of eight 10-25 minute treatment sessions. Participants will complete two sessions per week for four weeks and will be administered assessments at pre-treatment, one week post-treatment and at 3-month follow-up. We hypothesize that: 1) IBM will lead to greater reductions in BDD symptoms than the PMR condition; 2) IBM will lead to greater reductions in depression, anxiety and suicidal ideation than the PMR condition; 3) IBM will lead to greater reductions in threat interpretations and greater increases in benign interpretations than the PMR condition; 4) The effects of condition on BDD symptoms will be mediated by changes in BDD-related interpretation bias; and 5) The effects of training in the IBM condition will be maintained at the 3-month follow-up assessments.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Current diagnosis of Body Dysmorphic Disorder according to DSM-5 criteria
  • BDD-YBOCS score greater than or equal to 20
  • Fluent in English
  • No significant physical defect or flaw in appearance (e.g., disfiguration)
Exclusion Criteria
  • History of psychotic disorder, bipolar disorder, borderline personality disorder
  • Current substance use disorder
  • Unstable medication status (i.e. change in medication within the last month)
  • Concurrent psychotherapy for appearance concerns
  • Active and clinically significant suicidality

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Interpretation Bias Modification (IBM)Interpretation Bias ModificationTreatment consists of eight brief sessions. In Task 1, participants read unique scenarios ("You notice someone pointing in your direction"). A sentence meant to resolve the ambiguity will appear ("This person thinks they reco_nize you"). After filling in the missing letter, the interpretation is reinforced by requiring the participants to correctly answer "yes" or "no" to a comprehension question ("Is this person mocking you?"). In Task 2, participants are shown a word denoting a threatening ("mocking") or benign ("cheerful") interpretation. Participants are presented with an ambiguous scenario ("You hear people at a nearby table laughing") and asked to denote whether the word and the sentence are related. Participants will receive positive or negative feedback based on their response.
Progressive Muscle Relaxation (PMR)Progressive Muscle RelaxationParticipants will receive eight brief sessions of PMR. They will listen to a PMR script (Kassinove \& Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release 10 different muscle groups.
Primary Outcome Measures
NameTimeMethod
Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS; Phillips et al., 1997)change from baseline at one-week post treatment and 3-months post-treatment

Measures past-week BDD symptom severity

Secondary Outcome Measures
NameTimeMethod
Depressive Symptom Index-Suicidality Subscalechange from baseline at one-week post treatment and 3-months post-treatment

Measure severity of recent suicidality

Beck Anxiety Inventory (BAI; Steer & Beck, 1997)change from baseline at one-week post treatment and 3-months post-treatment

Measure anxious symptom severity

Beck Depression Inventory (BDI-II; Beck, Steer, & Brown, 1996)change from baseline at one-week post treatment and 3-months post-treatment

Measures depressive symptom severity

Body Dysmorphic Disorder Word Sentence Association Paradigm (BDD-WSAP; modified from Hindash & Amir, 2011)change from baseline at one-week post treatment and 3-months post-treatment

Measure of strength of BDD-related (i.e. evaluation- and appearance- related threat interpretation biases)

Trial Locations

Locations (1)

Florida State University Psychology Department

🇺🇸

Tallahassee, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath